# Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

> **NCT07564479** · PHASE2 · RECRUITING · sponsor: **Minia University** · enrollment: 50 (estimated)

## Conditions studied

- Cisplatin Nephrotoxicity
- Nephrotoxicity

## Interventions

- **DRUG:** Alpha-Lipoic Acid (ALA)

## Key facts

- **NCT ID:** NCT07564479
- **Lead sponsor:** Minia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-03
- **Final completion:** 2027-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07564479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07564479, "Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07564479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*